
Infinity Bio
Infinity Bio, Inc. is an antibody profiling company and developer of the up coming novel molecular display technology that employs self-assembling barcoded proteins and peptides.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor investor | €0.0 | round | |
* | $8.0m | Series A | |
Total Funding | 000k |
Related Content
Infinity Bio is a biotechnology company that has developed a proprietary platform for antibody reactome profiling, enabling the analysis of immune responses at a large scale. The company provides services to gain insights into the interactions between antibodies and antigens, particularly in the context of viral exposures and autoimmune diseases.
Its business model revolves around offering specialized services and analytics to researchers, pharmaceutical companies, and other entities in the life sciences sector. Infinity Bio generates revenue by providing access to its advanced technology and expertise in interpreting the complex data derived from antibody profiling. The company's key offerings include the VirSIGHT™ profiler, which focuses on the human virome, and the HuSIGHT™ profiler, which is geared towards understanding autoimmune responses. Additionally, Infinity Bio offers the creation of custom antigen libraries to meet specific research needs.
Keywords: antibody profiling, reactome, immune response, biotechnology, virome, autoimmune, antigen libraries, diagnostics, life sciences, immunology